Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Not listed Phase 2 Interventional

Phase 2b Study of Taxol Plus Sorafenib or Placebo in Patients With Advanced Breast Cancer

ClinicalTrials.gov ID: NCT00499525

Public ClinicalTrials.gov record NCT00499525. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 26, 2026, 4:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo When Administered in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Breast Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving paclitaxel together with sorafenib may kill more tumor cells. PURPOSE: This randomized phase II trial is studying how well paclitaxel works when given together with or without sorafenib in treating patients with locally recurrent or metastatic breast cancer.

Study identification

NCT ID
NCT00499525
Recruitment status
Not listed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Northwestern University
Other
Enrollment
180 participants

Conditions and interventions

Conditions

Interventions

Drug · Other

Eligibility (public fields only)

Age range
18 Years to 120 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2007
Primary completion
Nov 30, 2020
Completion
Nov 30, 2022
Last update posted
May 2, 2019

2007 – 2022

United States locations

U.S. sites
43
U.S. states
22
U.S. cities
42
Facility City State ZIP Site status
Northwest Alabama Cancer Center, PC - Muscle Shoals Muscle Shoals Alabama 35661 —
Highlands Oncology Group - Fayetteville Fayetteville Arkansas 72703 —
Pacific Cancer Medical Center, Incorporated Anaheim California 92801 —
Pacific Coast Hematology/Oncology Medical Group, Incorporated Fountain Valley California 92708 —
Desert Hematology-Oncology Medical Group, Incorporated Rancho Mirage California 92270 —
Sutter Cancer Center Sacramento California 95816 —
Cancer Prevention and Treatment Center at Dominican and Watsonville Community Hospital Soquel California 95073 —
Not listed St. Helena California 94574 —
Helen and Harry Gray Cancer Center at Hartford Hospital Hartford Connecticut 06102-5037 —
Eastern Connecticut Hematology and Oncology Associates Norwich Connecticut 06360 —
Medical Oncology and Hematology, PC at Harold Leever Cancer Center Waterbury Connecticut 06708 —
George Washington University Cancer Institute Washington D.C. District of Columbia 20037 —
Pasco Hernando Oncology Associates, PA - Brooksville Brooksville Florida 34613 —
Pasco Hernando Oncology Associates, PA - New Port Richey New Port Richey Florida 34652 —
Northeast Georgia Cancer Care, LLC - Medical Oncology Athens Georgia 30607 —
Mountain States Tumor Institute at St. Luke's Regional Medical Center Boise Idaho 83712 —
Hematology-Oncology Associates of Illinois Chicago Illinois 60611-2998 —
Robert H. Lurie Comprehensive Cancer Center at Northwestern University Chicago Illinois 60611-3013 —
Decatur Memorial Hospital Cancer Care Institute Decatur Illinois 62526 —
Cancer Institute at Alexian Brothers Elk Grove Village Illinois 60007-3397 —
Medical and Surgical Specialists, LLC Galesburg Illinois 61401 —
Hinsdale Hematology Oncology Associates Hinsdale Illinois 60521 —
Midwest Center for Hematology/Oncology Joliet Illinois 60432 —
Kellogg Cancer Care Center Oak Park Illinois 60302 —
Hematology/Oncology of the North Shore at Gross Point Medical Center Skokie Illinois 60076 —
Fort Wayne Medical Oncology and Hematology Fort Wayne Indiana 46885-5099 —
Family Medicine of Vincennes Clinical Trial Center Vincennes Indiana 47591 —
Kentuckiana Cancer Institute, PLLC Louisville Kentucky 40202 —
Mary Bird Perkins Cancer Center - Baton Rouge Baton Rouge Louisiana 70809-3482 —
Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center Columbia Missouri 65201 —
Nebraska Hematology-Oncology, PC Lincoln Nebraska 68510-2482 —
Essex Oncology of North Jersey Belleville New Jersey 07109 —
Sussex County Medical Associates - Sparta Sparta New Jersey 07871 —
Piedmont Hematology-Oncology Associates Winston-Salem North Carolina 27103 —
Tri-County Hematology/Oncology Associates, Incorporated Canton Ohio 44718 —
Hematology Oncology Consultants, Incorporated Columbus Ohio 43235 —
North Coast Cancer Care, Incorporated Sandusky Ohio 44870 —
Hematology and Oncology Associates of Rhode Island Cranston Rhode Island 02920 —
West Clinic - East Memphis Memphis Tennessee 38120 —
Patients' Comprehensive Cancer Center - Carrollton Carrollton Texas 75010-4602 —
Oncology Consultants - Memorial City Houston Texas 77024 —
Cascade Cancer Center at Evergreen Hospital Medical Center Kirkland Washington 98034-3013 —
Gundersen Lutheran Center for Cancer and Blood La Crosse Wisconsin 54601 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00499525, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 2, 2019 · Synced Sep 26, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00499525 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →